课题基金 / 基金详情

Pre-clinical evaluation of the efficacy of combined THC and CBDA to treat nausea in veterinary medicine

Pre-clinical evaluation of the efficacy of combined THC and CBDA to treat nausea in veterinary medicine
THC 和 CBDA 联合治疗兽医恶心疗效的临床前评估
批准号:
470199-2014
负责人:
Parker, Linda
金额:
$1.82万
依托单位:
依托单位国家:
加拿大
项目类别:
Engage Grants Program
财政年份:
2014
资助国家:
加拿大
项目状态:
已结题
起止时间:
2014-01-01 至 2015-12-31

项目摘要

项目成果

Parker, Linda的其他基金

相似基金

相关文献

中文摘要
翻译
几千年来,大麻一直被用来治疗恶心和呕吐。事实上,这种症状是第一个获得批准的医用大麻处方。大麻中的主要精神活性成分是四氢大麻二酚(THC),它具有抗恶心和止吐的特性。然而,最近的研究表明,大麻中的非精神活性化合物大麻二酚(CBD)和大麻二酸(CBDA)也可以减少恶心和呕吐。事实上,CBDA在减少恶心和呕吐方面的效力是CBD的1000倍,但没有精神运动作用。CBDA是CBD的前体,在工厂加热前发现。虽然在大麻植物中发现的60多种大麻类化合物中的一些已经单独进行了测试,但关于这些化合物组合对恶心和呕吐的影响的研究很少。在这里,我们建议评估THC:CBDA剂量的不同组合比任何一种单独使用更有效地减少恶心的潜力。这些实验的结果将提供
英文摘要
Cannabis has been used to treat nausea and vomiting for thousands of years. Indeed, this symptom was the first to receive approval for medical marijuana prescriptions. The primary psychoactive ingredient in cannabis is tetrahydrocannabidiol (THC) which has anti-nausea and anti-emetic properties. However, recently, research has shown that the non-psychoactive compounds in cannabis cannabidiol (CBD) and cannabidiolic acid (CBDA) also reduce nausea and vomiting. Indeed, CBDA is 1000 times more potent in reducing nausea and vomiting than CBD, but has no psychomotor effects. CBDA is the precursor to CBD that is found in the plant before it is heated. Although some of the over 60 cannabinoid compounds found in the cannabis plant have been tested alone, there has been very little research on the effects of combinations of these compounds on nausea and vomiting. Here we propose to evaluate the potential of various combinations of THC:CBDA doses to more effectively reduce nausea than either agent on its own. The results of these experiments will provide
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aversion learning in rats and shrews
  • 批准号:
    RGPIN-2016-03629
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $4.44万
  • 财政年份:
    2022
  • 负责人:
    Parker, Linda
  • 依托单位:
Aversion learning in rats and shrews
  • 批准号:
    RGPIN-2016-03629
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $4.44万
  • 财政年份:
    2021
  • 负责人:
    Parker, Linda
  • 依托单位:
Aversion learning in rats and shrews
  • 批准号:
    RGPIN-2016-03629
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $4.44万
  • 财政年份:
    2020
  • 负责人:
    Parker, Linda
  • 依托单位:
Aversion learning in rats and shrews
  • 批准号:
    RGPIN-2016-03629
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $4.44万
  • 财政年份:
    2019
  • 负责人:
    Parker, Linda
  • 依托单位:
国内基金
海外基金
"胚胎/生殖细胞发育特性激活”促进“神经胶质瘤恶变”的机制及其临床价值研究
  • 批准号:
    82372327
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    马展
  • 依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
  • 批准号:
    82372328
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    项盈
  • 依托单位:
自身免疫性T细胞的抗原决定簇在抗肾小球基底膜病发病中的启动机制
  • 批准号:
    81170645
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2011
  • 负责人:
    崔昭
  • 依托单位:
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data